STANDARD BIOTOOLS INC (LAB)
US34385P1084 - Common Stock
Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools to Participate in Upcoming Investor Conferences...
LAB Stock Earnings: Standard BioTools Reported Results for Q2 2024
Standard BioTools just reported results for the second quarter of 2024.
LAB Stock Earnings: Standard BioTools Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Standard BioTools (NASDAQ:LAB) just reported results for the second quarter of ...
Standard BioTools Announces Senior Leadership Changes
Standard BioTools Announces Senior Leadership Changes...
Standard BioTools Reports Second Quarter 2024 Financial Results
Standard BioTools Reports Second Quarter 2024 Financial Results...
Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024
Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024...
Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers
SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased...
Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools to Participate in Upcoming Investor Conferences...
Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)...
LAB Stock Earnings: Standard BioTools Reported Results for Q1 2024
Standard BioTools just reported results for the first quarter of 2024.
LAB Stock Earnings: Standard BioTools Reported Results for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Standard BioTools (NASDAQ:LAB) just reported results for the first quarter of 2...
Standard BioTools Reports First Quarter 2024 Financial Results
Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025Delivered...
Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth
Company expects to achieve $45-$50 million in annualized operating expense savings in fiscal 2025Management to discuss first quarter 2024 financial...
Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging
New advancements, including automation, aim to fast-forward spatial biology...
Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it has entered into a multi-year engagement with global biopharmaceutical company Bristol Myers Squibb for use of the SomaScan® Platform as a tool for clinical trials in multiple therapeutic areas through 2026.
Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock
SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today...
Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced financial results for the fourth quarter and fiscal year ended December 31, 2023.
Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools to Participate in Upcoming Investor Conferences...
Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024...
Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine
Increasing access to Imaging Mass Cytometry in pharmaceutical and clinical research settings...
Standard BioTools files to sell 38.43M shares for holders (NASDAQ:LAB)
Read about Standard BioTools (LAB) filing a prospectus for the proposed resale of 38.43M shares of its common stock by selling stockholders.
Standard BioTools expects over 10% growth in 2023 core revenue (NASDAQ:LAB)
Standard BioTools expects core revenue growth of over 10% in 2023, with revenue projected at ~$106M.
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue
Achieving scale with pro forma full year 2023 revenue of approximately $192 million...
Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools
Establishes Leading Platform of Complementary Multi-omic Technologies with Enhanced Scale and Commercial Reach; Strengthened Balance Sheet to Self-Fund...
Standard BioTools Stockholders Approve Merger with SomaLogic
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to...
SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting
/PRNewswire/ -- SomaLogic, Inc. (Nasdaq: SLGC) ("the Company"), a leader in proteomics technology, today announced that, based on the preliminary vote count...
Glass Lewis Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic
SOUTH SAN FRANCISCO, Calif., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to...
SomaLogic board urges shareholders to approve Standard Bio Tools merger (NASDAQ:SLGC)
SomaLogic’s (SLGC) board of directors has issued an open letter to stockholders urging them to vote for a proposed merger with Standard Bio Tools (LAB). Read more here.
SomaLogic founder, CTO urge shareholders to vote against merger (NASDAQ:SLGC)
SomaLogic (SLGC) founder Larry Gold and Chief Technology Officer Jason Cleveland urged shareholders in an open letter released Thursday to vote against a propos
Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools
/PRNewswire/ -- Dr. Larry Gold, the founder of SomaLogic, Inc. ("SomaLogic" or the "Company") (Nasdaq: SLGC) and Dr. Jason Cleveland, SomaLogic's current Chief...
SomaLogic Issues Statement Correcting Madryn Asset Management's Misleading Disclosure
/PRNewswire/ -- SomaLogic, Inc. (Nasdaq: SLGC), a leader in proteomics technology, today issued the following statement in response to a press release issued...